Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease

Abstract

Objective: To investigate the effects of hydroxychloroquine (HCQ) in Chinese patients with systemic lupus erythematosus who were either on a low dose of prednisone or not on prednisone.

Methods: 65 consecutive Chinese lupus patients without features of nephritis underwent assessment of the fasting serum lipid profile, including total cholesterol (TC), triglycerides (TG), HDL-cholesteorl (HDL-C), LDL-cholesterol (LDL-C), apolipoprotein A-1 (apo A-1), apolipoprotein B (apo B) and lipoprotein (a) (Lp(a)).

Results: 44/65 (67.7%) patients were on HCQ with a dose of 244 86 mg daily and 34/65 (52.3%) patients were on 4.3 + 2.6 mg daily of prednisone. The percentages of patients taking prednisone and the mean dose in those patients receiving this treatment were not different between the groups with or without HCQ treatment. TG tended to be lower in those patients on HCQ (median and interquartile range) (1.0 (0.7-1.4) mmol/L vs 1.2 (0.8-1.6) mmol/L), but there were no significant differences in TC or other lipid parameters including Lp(a) between the 2 groups of patients with or without HCQ treatment.

Conclusion: HCQ had no significant effect on the serum lipid profile in these lupus patients with mild or inactive disease. This finding probably reflects the low doses of corticosteroid used and a lower background lipid level in this population.

Keywords

systemic lupus erythematosus fasting lipids hydroxychloroquine

Get full access to this article

View all access options for this article.

References

1 Urowitz MB , Bookman AAM , Koehler BE et al. The bimodal mortality pattern of systemic lupus erythematosus . Am J Med 1976; 60: 221-225 .

2 Wallace DJ , Metzger AL , Stecher VJ et al. Cholesterol-lowering effects of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med 1990; 89: 322-326 .

3 Petri M , Lakatta C , Magder L , Goldman D . Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis . Am J Med 1994; 96: 254-259 .

4 Rahman P , Gladman DD , Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs . J Rheumatol 1999; 26: 325-330 .

5 Nossen JO , Rustan AC , Barnard T , Drevon CA . Inhibition of chloroquine of the secretion of very low density lipoproteins by cultured rat hepatocytes . Biochim Biophys Acta 1984; 803: 11-20 .

6 Chen HW , Leonard DA . Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells . J Biol Chem 1984; 259: 8156-8162 .

7 Goldstein JL , Brunschede GY , Brown MS . Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339 . J Biol Chem 1975; 250: 7854-7862 .

8 Powrie JK , Shojaee-Moradie F , Watts GF et al. Effects of chloroquine on the dyslipidaemia of non-insulin-dependent diabetes mellitus . Metabolism 1993; 42: 415-419 .

9 Hodis HN , Quismorio FP Jr , Wickham E , Blankenhorn DH . The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus . J Rheumatol 1993; 20: 661-665 .

10.

10 Ettinger WH , Goldberg AP , Appelbaum-Bowden D , Hazzard WR . Dyslipoproteinaemia in systemic lupus erythematosus. Effect of corticosteroids . Am J Med 1987; 83: 503-508 .

11.

11 Borba EF , Bonfa E . Dyslipoproteinaemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies . Lupus 1997; 6: 533-539 .

12.

12 Borba EF , Santos RD , Bonfa E et al. Lipoprotein(a) levels in systemic lupus erythematosus . J Rheumatol 1994; 21: 220-223 .

13.

13 Scanu AM , Lawn RM , Berg K . Lipoprotein(a) and atherosclerosis . Ann Intern Med 1991; 115: 209-218 .

14.

14 Loscalzo J , Weinfeld M , Fless GM , Scanu AM . Lipoprotein(a), fibrin binding, and plasminogen activation . Arteriosclerosis 1990; 10: 240-245 .

15.

15 Kawai S , Mizushima Y , Kaburaki J . Increased serum lipoprotein(a) levels in systemic lupus erythematosus with myocardial and cerebral infarction . J Rheumatol 1995; 22: 1210-1211 (letter).

16.

16 Atsumi T , Khamashta MA , Andujar C et al. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome . J Rheumatol 1998; 25: 69-73 .

17.

17 Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

18.

18 Friedewald WT , Levy RI , Fredrickson DS . Estimation of the plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge . Clin Chem 1972; 18: 499-512 .

19.

19 Kurzrock R , Rohde MF , Quesada JR et al. Recombinant gamma-interferon induced hypertriglyceridaemia and inhibits post-heparin lipase activity in cancer patients . J Exp Med 1986; 164: 1093-1101 .

20.

20 Beutler BA , Cerami A . Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-LI cells . J Immunol 1985; 135: 3969-3971 .

21.

21 Ettinger WH , Hazzard WR . Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men . Metabolism 1988; 37: 1055-1058 .